BioPharma Dive1d
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Vertex Pharmaceuticals' SWOT analysis: stock poised for growth amid pipeline expansion
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...
Yahoo Finance5d
Vertex (VERX) Upgraded to Strong Buy: Here's Why
Vertex (VERX) could be a solid addition to your ... the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by ...
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...
NewsX1d
How Much Will Newly Non-Opioid Painkiller Approved By FDA Cost You?
The FDA granted approval for Journavx after clinical trials demonstrated its effectiveness in post-surgical pain relief ...
Hosted on MSN5d
Vertex (VERX) Upgraded to Strong Buy: Here's Why
Vertex (VERX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...